NativeMed review

NativeMed's own FDA warning is part of the review

FDA issued warning letter #728287, to NativeMed LLC dba NativeMed over false or misleading claims and misbranding in telehealth marketing. This is NativeMed's own letter, not a letter to the unrelated Native Remedies business. Its relevance is how the seller describes prescription products, rather than proof of a particular patient's outcome. A warning letter does not establish that every prescription is inappropriate or that the company has closed. It does mean the regulatory disclosure belongs beside the sales offer, especially when deciding how much confidence to place in promotional claims about compounded medication.

NativeMed advertises compounded semaglutide starting at $149 monthly and tirzepatide starting at $183. Those figures have been presented as sale prices against regular reference amounts of $299 and $399, without a clear public sale end date. Do not assume the lower amount is a permanent renewal rate or that the crossed-out amount necessarily becomes the next charge. Request the exact current offer, applicable dose and future billing amount before enrolling. A lower sale price can be useful, but its value depends on how long it applies and whether your prescription qualifies for the advertised starting tier.

A simple medication bill still needs a complete quote

The company states that no membership fee is added to the medication price, with consultation included in the program description. That is different from a service advertising a small clinical subscription while charging separately for the drug. It still leaves questions about the total at your prescribed dose, supply quantity and any fulfillment charges. Ask whether the quoted amount is for a calendar month or another defined supply interval and whether a transfer patient receives the same offer as someone beginning treatment. Keep the medication, care and renewal information together rather than relying only on a sale card.

The public program describes US-based pharmacies without naming the specific compounder. Ask which pharmacy would fill your prescription and who is responsible for clinical questions after dispensing. A general domestic-pharmacy claim is not FDA approval of a compounded preparation, and it does not identify the organization handling your order. NativeMed sells GLP-1 treatments alongside NAD+, sexual-health and other medications, rather than presenting a dedicated weight-only clinic. That broad catalog may be convenient for some patients, but products sharing a storefront are not evidence that a combined treatment is needed or included in your price.

Confirm location and cancellation before the promotion decides for you

NativeMed does not publish a complete state list in its main program information. Establish eligibility for your address before completing a full intake, particularly if you travel or expect to relocate. Obtain the actual cancellation deadline, automatic-renewal rules and refund conditions for the selected offer too. A no-membership statement does not establish that a processed prescription is refundable. Ask what happens before provider approval, after the pharmacy receives an order and after shipment. Those stages can have different consequences, so a general promise of convenient care should not be treated as the entire purchase contract.

There is no specific postpartum, breastfeeding or PCOS pathway described in the GLP-1 service. Someone whose main question is hormonal timing should bring that to the clinician before choosing the sale or a supply duration. NativeMed is most relevant to someone considering its particular compounded offer who can resolve the pharmacy, state and ongoing-price questions. The low displayed rate should not overshadow the FDA letter or the absence of a clear sale duration. Compare a complete current quote with other programs, and judge the clinical relationship separately from the apparent discount between the lower and crossed-out prices.